Brokerages Set $60.50 Price Target for 10x Genomics (NYSE:TXG)

10x Genomics (NYSE:TXG) has been assigned a consensus broker rating score of 1.00 (Strong Buy) from the four brokers that cover the company, Zacks Investment Research reports. Four investment analysts have rated the stock with a strong buy recommendation.

Analysts have set a 1 year consensus target price of $60.50 for the company and are expecting that the company will post ($0.13) EPS for the current quarter, according to Zacks. Zacks has also given 10x Genomics an industry rank of 86 out of 255 based on the ratings given to its competitors.

Several research firms have weighed in on TXG. Cowen began coverage on shares of 10x Genomics in a research note on Monday, October 7th. They issued an “outperform” rating and a $55.00 price target for the company. Evercore ISI began coverage on shares of 10x Genomics in a research note on Tuesday, September 24th. They issued an “outperform” rating and a $70.00 price target for the company. Bank of America began coverage on shares of 10x Genomics in a research note on Monday, October 7th. They issued a “buy” rating and a $62.00 price target for the company. Finally, JPMorgan Chase & Co. began coverage on shares of 10x Genomics in a research note on Monday, October 7th. They issued an “overweight” rating and a $55.00 price target for the company.

10x Genomics stock traded up $0.44 during mid-day trading on Monday, hitting $52.94. The company’s stock had a trading volume of 161,613 shares, compared to its average volume of 409,204. 10x Genomics has a 12 month low of $45.11 and a 12 month high of $63.38.

In other news, Director Bryan E. Roberts acquired 30,000 shares of the stock in a transaction dated Friday, September 13th. The stock was purchased at an average cost of $23.31 per share, with a total value of $699,300.00. Also, major shareholder Foresite Capital Fund I, L.P. acquired 187,500 shares of the stock in a transaction dated Thursday, September 12th. The shares were purchased at an average cost of $39.00 per share, with a total value of $7,312,500.00. Insiders acquired 517,500 shares of company stock valued at $19,711,800 over the last three months.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems. It offers chromium instruments, enzymes, reagents, microfluidic chips, and other consumable products, as well as software for analyzing biological systems.

Featured Article: Why Invest in Dividend Achievers?

Get a free copy of the Zacks research report on 10x Genomics (TXG)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter.